Results 41 to 50 of about 10,028,727 (294)

Proportion of time in therapeutic range (%) for patients on vitamin K antagonists with and without concomitant antiplatelet therapy.

, 2016
Proportion of time in therapeutic range (%) for patients on vitamin K antagonists with and without concomitant antiplatelet therapy.
David A. Fitzmaurice (414003), Sebastian M. Schellong (3280809), A. John Camm (480892), Pantep Angchaisuksiri (3280821), Sylvia Haas (414005), Samuel Z. Goldhaber (414004), Shinya Goto (82609), Janina Stepinska (3280812), Alexander G. G. Turpie (414008), Martin van Eickels (414009), Barry Jacobson (3280827), Lorenzo G. Mantovani (414007), Hugo ten Cate (280615), Gloria Kayani (414012), Harald Darius (78727), Frank Misselwitz (414010), Karen Pieper (3280815), Jean-Pierre Bassand (414002), Ramon Corbalan (3280824), Ajay K. Kakkar (414000), Gabriele Accetta (3280818)   +20 more
core   +1 more source

The Shewanella oneidensis Fic enzyme SoFic targets the switch‐I region of EF‐Tu for AMPylation

FEBS Letters, EarlyView.
Fic enzymes mediate diverse post‐translational modifications across all domains of life, including AMPylation. Prokaryotic EF‐Tu can be AMPylated and deAMPylated by the conserved Fic enzyme SoFic. Structural and biochemical approaches were used to characterize the effect of AMPylation on EF‐Tu, SoFic's enzymatic activities, and the enzyme‐target ...
Svenja Runge, Vivian Pogenberg, Alexander Baumgart, Bente Siebels, Hartmut Schlüter, Michael Hecht‐Bucher, Aymelt Itzen   +6 more
wiley   +1 more source

New oral anticoagulants in the prevention of stroke

Studia Medyczne, 2013
Atrial fibrillation is associated with a few folds higher risk of stroke. Traditional vitamin K antagonists used in the prevention of stroke in patients with non-valvular atrial fibrillation are often not efficient enough due to their interactions with a 
Konrad Jarząbek, Dawid Bąkowski, Beata Wożakowska-Kapłon   +2 more
doaj   +1 more source

Vitamin K antagonists and non-vitamin K antagonists (new anticoagulants) use in clinical practice and their most common complications [PDF]

, 2018
Aim: to evaluate trends and possibilities of anticoagulants usage and to evaluate the most often complication caused by it - bleeding and other side effects for patients of all ages and genders. Objectives: 1.
Bartašius, Tomas
core  

The heterodimeric amino acid transporters (HAT) of the SLC7/SLC3 family: A structure−function relationships and relevance to human pathology

FEBS Letters, EarlyView.
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise, Tiziano Mazza, Raffaella Scanga, Lara Console, Michele Galluccio, Cesare Indiveri   +5 more
wiley   +1 more source

Vitamin K antagonists and cardiovascular calcification: A systematic review and meta-analysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundMany patients treated with Vitamin K antagonists (VKA) for anticoagulation have concomitant vascular or valvular calcification. This meta-analysis aimed to evaluate a hypothesis that vascular and valvular calcification is a side-effect of VKA ...
Nina D. Kosciuszek, Nina D. Kosciuszek, Daniel Kalta, Mohnish Singh, Olga V. Savinova   +4 more
doaj   +1 more source

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance [PDF]

, 2013
Nancy El-Helou, Amal Al-Hajje, Rola Ajrouche, Sanaa Awada, Samar Rachidi, Salam Zein, Pascale SalamehClinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Lebanese University, Beirut, LebanonBackground: Adverse drug events (ADE) occur ...
Awada S, El-Helou N, Ajrouche R, Salameh P, Zein S, Rachidi S, Al-Hajje A   +6 more
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Mechanisms of arterial remodeling: lessons from genetic diseases

Frontiers in Genetics, 2012
Vascular disease is still the leading cause of morbidity and mortality in the Western world, and the primary cause of myocardial infarction, stroke, and ischemia.
Bernard eVan Varik, Roger eRennenberg, Chris eReutelingsperger, Abraham eKroon, Peter ede Leeuw, Leon J Schurgers   +5 more
doaj   +1 more source

Beyond deficiency:Potential benefits of increased intakesof vitamin K for bone and vascular health [PDF]

, 2004
Vitamin K is wellknown for its role in the synthesisof a number of blood coagulationfactors.During recent years vitaminK-dependent proteins werediscovered to be of vital importancefor bone and vascular health.Recommendations for dietary vitaminK intake ...
Vermeer, C, Weber, P, Zittermann, A, Shearer, M, Szulc, P, Walter, P, Stocklin, E, Bolton-Smith, C, Rambeck, W, Hodges, S   +9 more
core